cdphp glp 1 coverage GLP-1s and The Payer Predicament Navigating Changes to GLP-1 Medication
Description
GLP-1 itself is unsuitable as a drug due to a short half-life in the blood
Moreover, enhanced physician confidence and guideline support for wider therapeutic applications propel earlier adoption in a large number of healthcare facilities and payer systems, worldwide
Here we highlight data informing the safety, efficacy, and potential utility of new and emerging glucagon-like peptide-1 medicines
She says the drug, which is used to treat type 2 diabetes, has worked out great for her
